Clinical Trial Update: A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab [Phase 1]

View source ↗

Summary

This clinical trial entry describes NTX-1088, a monoclonal antibody targeting CD155, studied as monotherapy and in combination with pembrolizumab in cancer pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• NTX-1088 (NTX-1088)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Nectin Therapeutics Ltd | Conditions: Cancer, Tumor, Solid | Phase 1 | Status: RECRUITING